Amid an intensive capital mobilization program driving next-generation weight-loss manufacturing expansions, global contract development and manufacturing organization (CDMO) CordenPharma has finalized a definitive agreement to acquire U.S.-based specialized peptide contractor AmbioPharm. While the final financial parameters of the transaction were withheld by the participating entities, the strategic buyout positions CordenPharma to fully absorb AmbioPharm’s operating production facilities in South Carolina (United States) and Shanghai (China), while integrating a technical workforce of approximately 400 employees into its global infrastructure.
The core administrative parameters, biochemical engineering capacities, and infrastructural roadmaps defining CordenPharma’s current operations feature:
-
Advanced Technical Optimization: The integration of AmbioPharm’s specialized platform enables CordenPharma to diversify its core peptide synthesis methodologies. The combined operational matrix offers international clients highly flexible options to customize engineering blueprints for complex, long-chain, and high-purity peptide active pharmaceutical ingredients (APIs).
-
Geographic Supply Chain Diversification: Capturing the Shanghai asset grants CordenPharma its foundational commercial foothold inside China, successfully expanding its footprint across a third continent beyond the 11 manufacturing plants it currently runs throughout Europe and the United States. Domestically within the U.S. market, the South Carolina site establishes CordenPharma’s second dedicated peptide production plant, complementing its long-standing Boulder, Colorado facility purchased from Roche in 2011. This dual-site domestic orientation positions the CDMO to deliver end-to-end, fully U.S.-sourced peptide API supply architectures for macro commercializations.
-
Capital Allocation Timeline: The acquisition directly advances a macro three-year, €900 million (approximately $981 million) capital investment strategy instituted by CordenPharma in 2024 to rapidly scale its global GLP-1 peptide output. A significant tranche of this financing — totaling €500 million — was deployed in March 2025 to construct a state-of-the-art peptide complex near Basel, Switzerland. This European facility is projected to kick off formal commercial supply in 2028 and generate roughly 300 clinical manufacturing jobs.
-
Commercial Momentum and Agonist Pipelines: Accelerating global demand for incretin-based metabolic therapies, illustrated by blockbusters like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, has catalyzed a wave of development pipelines across the metabolic disease landscape. Highlighting this business momentum, prominent obesity drug developer Viking Therapeutics finalized a $150 million commercial agreement running through 2028 for CordenPharma to manufacture its proprietary dual GIP/GLP-1 receptor agonist, VK2735.
Executive leadership at CordenPharma has not publicly finalized an exact target deadline for the formal regulatory closing of the corporate acquisition.